Carmenta: Preempting preeclampsia

Carmenta's diagnostic could confirm preeclampsia, speeding treatment decisions

The diagnosis of preeclampsia in pregnant women currently relies on detection of symptoms that do not reliably differentiate it from other conditions, thereby delaying treatment decisions. Carmenta Bioscience Inc.'s panel of serum markers could solve this problem by confirming a diagnosis of preeclampsia quickly and accurately.

Preeclampsia occurs in about 5% of pregnant women and can lead to life-threatening seizures (eclampsia). The condition is usually diagnosed in the second or third trimester when clinical symptoms of

Read the full 753 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE